Adjunctive Rufinamide in Children with Lennox-Gastaut Syndrome: A Literature Review

Ganna Balagura, Antonella Riva, Francesca Marchese, Alberto Verrotti, Pasquale Striano

Research output: Contribution to journalReview articlepeer-review


Lennox-Gastaut syndrome (LGS) is a severe, childhood-onset, developmental epileptic encephalopathy, with different etiologies and co-morbidities. Seizure treatment in LGS represents a major challenge; new antiepileptic drugs (AEDs) are developed to especially address seizures resulting in high morbidity and mortality, such as drop seizures. Rufinamide (RFN) is one of the latest AEDs licensed for patients with LGS. Its mechanism of action involves sodium channels in a way that is unrelated to other AEDs. Here we discuss the use of adjunctive RFN in children and adolescents with LGS and its efficacy and safety profile, based on a systematic literature review. RFN shows a very favorable profile in terms of adverse events and drug-interactions in children. It is particularly effective on tonic-atonic seizures and spasms, impacting on the quality of life of the patients. Further studies are needed to clarify the interaction profile with the newest AEDs for LGS and to assess correlations between the etiology of LGS and drug response to individualize treatment and maximize efficacy.

Original languageEnglish
Pages (from-to)369-379
Number of pages11
JournalNeuropsychiatric Disease and Treatment
Publication statusPublished - 2020


Dive into the research topics of 'Adjunctive Rufinamide in Children with Lennox-Gastaut Syndrome: A Literature Review'. Together they form a unique fingerprint.

Cite this